25 XP   0   0   10

Vaccinex Inc
Buy, Hold or Sell?

Let's analyse Vaccinex together

PenkeI guess you are interested in Vaccinex Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vaccinex Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vaccinex Inc

I send you an email if I find something interesting about Vaccinex Inc.

Quick analysis of Vaccinex (30 sec.)










What can you expect buying and holding a share of Vaccinex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.46
Expected worth in 1 year
$-20.40
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$-18.95
Return On Investment
-342.0%

For what price can you sell your share?

Current Price per Share
$5.54
Expected price per share
$4.432 - $7.51
How sure are you?
50%

1. Valuation of Vaccinex (5 min.)




Live pricePrice per Share (EOD)

$5.54

Intrinsic Value Per Share

$-74.61 - $-1.15

Total Value Per Share

$-76.07 - $-2.61

2. Growth of Vaccinex (5 min.)




Is Vaccinex growing?

Current yearPrevious yearGrowGrow %
How rich?-$2.3m$5.1m-$7.5m-324.7%

How much money is Vaccinex making?

Current yearPrevious yearGrowGrow %
Making money-$20.2m-$19.7m-$529k-2.6%
Net Profit Margin-3,552.8%-19,722.0%--

How much money comes from the company's main activities?

3. Financial Health of Vaccinex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#891 / 1004

Most Revenue
#997 / 1004

Most Profit
#434 / 1004

Most Efficient
#902 / 1004

What can you expect buying and holding a share of Vaccinex? (5 min.)

Welcome investor! Vaccinex's management wants to use your money to grow the business. In return you get a share of Vaccinex.

What can you expect buying and holding a share of Vaccinex?

First you should know what it really means to hold a share of Vaccinex. And how you can make/lose money.

Speculation

The Price per Share of Vaccinex is $5.54. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vaccinex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vaccinex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.46. Based on the TTM, the Book Value Change Per Share is $-4.74 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vaccinex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-12.78-230.7%-12.78-230.7%-12.45-224.7%-15.54-280.4%-15.84-285.9%
Usd Book Value Change Per Share-4.74-85.5%-4.74-85.5%-1.40-25.3%-2.23-40.2%-0.18-3.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-4.74-85.5%-4.74-85.5%-1.40-25.3%-2.23-40.2%-0.18-3.3%
Usd Price Per Share0.66-0.66-0.64-1.85-1.61-
Price to Earnings Ratio-0.05--0.05--0.05--0.11--0.09-
Price-to-Total Gains Ratio-0.14--0.14--0.46--2.11--1.71-
Price to Book Ratio-0.46--0.46-0.20--0.93--0.54-
Price-to-Total Gains Ratio-0.14--0.14--0.46--2.11--1.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.54
Number of shares180
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-4.74-2.23
Usd Total Gains Per Share-4.74-2.23
Gains per Quarter (180 shares)-852.57-401.13
Gains per Year (180 shares)-3,410.26-1,604.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3410-34200-1605-1615
20-6821-68300-3209-3220
30-10231-102400-4814-4825
40-13641-136500-6418-6430
50-17051-170600-8023-8035
60-20462-204700-9627-9640
70-23872-238800-11232-11245
80-27282-272900-12836-12850
90-30692-307000-14441-14455
100-34103-341100-16045-16060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%3.05.00.037.5%3.05.00.037.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%3.05.00.037.5%3.05.00.037.5%

Fundamentals of Vaccinex

About Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Fundamental data was last updated by Penke on 2024-04-30 19:11:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vaccinex Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vaccinex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Vaccinex to the Biotechnology industry mean.
  • A Net Profit Margin of -3,552.8% means that $-35.53 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vaccinex Inc:

  • The MRQ is -3,552.8%. The company is making a huge loss. -2
  • The TTM is -3,552.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-3,552.8%TTM-3,552.8%0.0%
TTM-3,552.8%YOY-19,722.0%+16,169.2%
TTM-3,552.8%5Y-18,119.1%+14,566.3%
5Y-18,119.1%10Y-14,985.9%-3,133.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,552.8%-176.9%-3,375.9%
TTM-3,552.8%-211.5%-3,341.3%
YOY-19,722.0%-266.0%-19,456.0%
5Y-18,119.1%-401.1%-17,718.0%
10Y-14,985.9%-552.5%-14,433.4%
1.1.2. Return on Assets

Shows how efficient Vaccinex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vaccinex to the Biotechnology industry mean.
  • -557.7% Return on Assets means that Vaccinex generated $-5.58 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vaccinex Inc:

  • The MRQ is -557.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -557.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-557.7%TTM-557.7%0.0%
TTM-557.7%YOY-247.2%-310.5%
TTM-557.7%5Y-397.4%-160.4%
5Y-397.4%10Y-368.4%-29.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-557.7%-12.1%-545.6%
TTM-557.7%-11.7%-546.0%
YOY-247.2%-11.0%-236.2%
5Y-397.4%-13.2%-384.2%
10Y-368.4%-14.5%-353.9%
1.1.3. Return on Equity

Shows how efficient Vaccinex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vaccinex to the Biotechnology industry mean.
  • 0.0% Return on Equity means Vaccinex generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vaccinex Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-379.8%+379.8%
TTM-5Y-138.6%+138.6%
5Y-138.6%10Y-86.7%-52.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.4%+15.4%
TTM--15.0%+15.0%
YOY-379.8%-13.7%-366.1%
5Y-138.6%-17.8%-120.8%
10Y-86.7%-19.3%-67.4%

1.2. Operating Efficiency of Vaccinex Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vaccinex is operating .

  • Measures how much profit Vaccinex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vaccinex to the Biotechnology industry mean.
  • An Operating Margin of -4,014.9% means the company generated $-40.15  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vaccinex Inc:

  • The MRQ is -4,014.9%. The company is operating very inefficient. -2
  • The TTM is -4,014.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,014.9%TTM-4,014.9%0.0%
TTM-4,014.9%YOY-19,906.0%+15,891.1%
TTM-4,014.9%5Y-17,840.6%+13,825.7%
5Y-17,840.6%10Y-15,356.8%-2,483.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,014.9%-339.4%-3,675.5%
TTM-4,014.9%-221.5%-3,793.4%
YOY-19,906.0%-281.8%-19,624.2%
5Y-17,840.6%-408.0%-17,432.6%
10Y-15,356.8%-528.5%-14,828.3%
1.2.2. Operating Ratio

Measures how efficient Vaccinex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 41.15 means that the operating costs are $41.15 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vaccinex Inc:

  • The MRQ is 41.149. The company is inefficient in keeping operating costs low. -1
  • The TTM is 41.149. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ41.149TTM41.1490.000
TTM41.149YOY202.130-160.981
TTM41.1495Y179.858-138.709
5Y179.85810Y154.821+25.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ41.1493.076+38.073
TTM41.1493.246+37.903
YOY202.1303.609+198.521
5Y179.8585.190+174.668
10Y154.8216.896+147.925

1.3. Liquidity of Vaccinex Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vaccinex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.57 means the company has $0.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vaccinex Inc:

  • The MRQ is 0.566. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.566. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.566TTM0.5660.000
TTM0.566YOY2.948-2.381
TTM0.5665Y1.824-1.258
5Y1.82410Y1.750+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5663.802-3.236
TTM0.5664.158-3.592
YOY2.9485.249-2.301
5Y1.8246.087-4.263
10Y1.7506.428-4.678
1.3.2. Quick Ratio

Measures if Vaccinex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vaccinex to the Biotechnology industry mean.
  • A Quick Ratio of 0.42 means the company can pay off $0.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vaccinex Inc:

  • The MRQ is 0.422. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.422. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.422TTM0.4220.000
TTM0.422YOY2.588-2.166
TTM0.4225Y1.633-1.212
5Y1.63310Y1.844-0.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4223.246-2.824
TTM0.4223.811-3.389
YOY2.5885.150-2.562
5Y1.6335.929-4.296
10Y1.8446.351-4.507

1.4. Solvency of Vaccinex Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vaccinex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vaccinex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.64 means that Vaccinex assets are financed with 163.6% credit (debt) and the remaining percentage (100% - 163.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vaccinex Inc:

  • The MRQ is 1.636. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.636. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.636TTM1.6360.000
TTM1.636YOY0.349+1.287
TTM1.6365Y0.990+0.647
5Y0.99010Y1.093-0.103
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6360.351+1.285
TTM1.6360.343+1.293
YOY0.3490.278+0.071
5Y0.9900.366+0.624
10Y1.0930.379+0.714
1.4.2. Debt to Equity Ratio

Measures if Vaccinex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vaccinex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vaccinex Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.536-0.536
TTM-5Y0.173-0.173
5Y0.17310Y0.108+0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.402-0.402
TTM-0.415-0.415
YOY0.5360.351+0.185
5Y0.1730.442-0.269
10Y0.1080.469-0.361

2. Market Valuation of Vaccinex Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vaccinex generates.

  • Above 15 is considered overpriced but always compare Vaccinex to the Biotechnology industry mean.
  • A PE ratio of -0.05 means the investor is paying $-0.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vaccinex Inc:

  • The EOD is -0.433. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.052. Based on the earnings, the company is expensive. -2
  • The TTM is -0.052. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.433MRQ-0.052-0.381
MRQ-0.052TTM-0.0520.000
TTM-0.052YOY-0.0520.000
TTM-0.0525Y-0.106+0.054
5Y-0.10610Y-0.091-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.433-2.413+1.980
MRQ-0.052-2.573+2.521
TTM-0.052-2.766+2.714
YOY-0.052-3.948+3.896
5Y-0.106-6.374+6.268
10Y-0.091-6.660+6.569
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vaccinex Inc:

  • The EOD is -0.507. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.061. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.061. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.507MRQ-0.061-0.446
MRQ-0.061TTM-0.0610.000
TTM-0.061YOY-0.053-0.008
TTM-0.0615Y-0.108+0.048
5Y-0.10810Y-0.096-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.507-3.085+2.578
MRQ-0.061-3.312+3.251
TTM-0.061-3.529+3.468
YOY-0.053-5.200+5.147
5Y-0.108-8.251+8.143
10Y-0.096-8.842+8.746
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vaccinex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.46 means the investor is paying $-0.46 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vaccinex Inc:

  • The EOD is -3.798. Based on the equity, the company is expensive. -2
  • The MRQ is -0.456. Based on the equity, the company is expensive. -2
  • The TTM is -0.456. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.798MRQ-0.456-3.342
MRQ-0.456TTM-0.4560.000
TTM-0.456YOY0.197-0.652
TTM-0.4565Y-0.934+0.479
5Y-0.93410Y-0.537-0.397
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.7982.082-5.880
MRQ-0.4562.031-2.487
TTM-0.4562.076-2.532
YOY0.1972.688-2.491
5Y-0.9343.692-4.626
10Y-0.5374.104-4.641
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vaccinex Inc.

3.1. Institutions holding Vaccinex Inc

Institutions are holding 41.704% of the shares of Vaccinex Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31AIGH Capital Management, LLC5.00260.2149817061-273112-25.0522
2023-12-31Worth Venture Partners, LLC4.00470.235654079-63480-8.8467
2023-12-31Vanguard Group Inc0.295204822100
2023-12-31Renaissance Technologies Corp0.1965032100321000
2023-12-31Two Sigma Investments LLC0.0989016159161590
2023-12-31Geode Capital Management, LLC0.098601610020.0124
2023-12-31XTX Topco Ltd0.07190.001711737117370
2023-12-31Tower Research Capital LLC0.04080.0001665661221146.4419
2023-12-31Group One Trading, LP0.0056091600
2023-12-31UBS Group AG0.00210339-12271-97.3117
2023-12-31Royal Bank of Canada0.0018029400
2023-12-31Advisor Group Holdings, Inc.0.0014023400
2023-12-31Wells Fargo & Co0.00040683183.7838
2023-09-30SIMPLEX TRADING, LLC0.000305431134.7826
2023-12-31Morgan Stanley - Brokerage Accounts0.000102000
2023-09-30Cornerstone Planning Group LLC0.000101417.6923
2023-12-31JPMorgan Chase & Co0.00010107233.3333
2023-12-31Bank of America Corp004-63-94.0299
2023-09-30Creative Planning Inc000-733-100
2023-09-30State Street Corporation000-4760-100
Total 9.82110.45171604066-288229-18.0%

3.2. Funds holding Vaccinex Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31SSgA U.S. Extended Market Index Class I0.00550122000
2023-12-31Northern Trust Extended Eq Market Idx0.0045099700
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr0.0568090010.1112
2024-02-29Fidelity Extended Market Index0.0494078200
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0021046900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0017037710.266
2023-12-31SSgA U.S. Total Market Index Strategy0.00160352-8-2.2222
2024-02-29Fidelity Series Total Market Index0.0217034400
2024-02-29Fidelity Nasdaq Composite Index0.01180187-1-0.5319
2024-03-31State St US Extended Mkt Indx NL Cl C0.005608811.1494
2024-03-31NT Ext Equity Mkt Idx Fd - L0.004507211.4085
2023-12-31Northern Trust Wilshire 50000.0003063-878-93.305
2023-12-31NT US Market Cap Idx Fd - L0.000306300
2024-02-29Spartan Total Market Index Pool E0.003405400
2024-03-31State St US Ttl Mkt Indx SL Cl I0.0011018212.5
2023-12-31BNYM Mellon SL Market Completion UC10.000101700
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000101500
2023-12-31BNYM Mellon NSL Mkt Completion Fund Inst006120
Total 0.170506024-880-14.6%

3.3. Insider Transactions

Insiders are holding 6.773% of the shares of Vaccinex Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-19Albert FriedbergBUY2824.73
2023-12-26Strydonck Gerald E. VanSELL22410.08
2023-10-03Albert FriedbergBUY21428514
2023-10-03Maurice ZaudererBUY35713.02

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vaccinex Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---4.736-4.7360%-1.401-70%-2.228-53%-0.182-96%
Book Value Per Share---1.459-1.4590%3.278-145%0.683-314%1.235-218%
Current Ratio--0.5660.5660%2.948-81%1.824-69%1.750-68%
Debt To Asset Ratio--1.6361.6360%0.349+369%0.990+65%1.093+50%
Debt To Equity Ratio----0%0.536-100%0.173-100%0.108-100%
Dividend Per Share----0%-0%-0%-0%
Eps---12.782-12.7820%-12.448-3%-15.536+22%-15.839+24%
Free Cash Flow Per Share---10.920-10.9200%-12.102+11%-15.342+40%-14.913+37%
Free Cash Flow To Equity Per Share---3.065-3.0650%-1.387-55%-2.302-25%-0.349-89%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.148--------
Intrinsic Value_10Y_min---74.612--------
Intrinsic Value_1Y_max---10.248--------
Intrinsic Value_1Y_min---13.496--------
Intrinsic Value_3Y_max---23.068--------
Intrinsic Value_3Y_min---35.577--------
Intrinsic Value_5Y_max---26.579--------
Intrinsic Value_5Y_min---52.038--------
Market Cap8777022.000+88%1053242.6401053242.6400%1021081.350+3%2937070.398-64%2557476.079-59%
Net Profit Margin---35.528-35.5280%-197.220+455%-181.191+410%-149.859+322%
Operating Margin---40.149-40.1490%-199.060+396%-178.406+344%-153.568+282%
Operating Ratio--41.14941.1490%202.130-80%179.858-77%154.821-73%
Pb Ratio-3.798-733%-0.456-0.4560%0.197-332%-0.934+105%-0.537+18%
Pe Ratio-0.433-733%-0.052-0.0520%-0.0520%-0.106+105%-0.091+75%
Price Per Share5.540+88%0.6650.6650%0.645+3%1.854-64%1.614-59%
Price To Free Cash Flow Ratio-0.507-733%-0.061-0.0610%-0.053-13%-0.108+78%-0.096+58%
Price To Total Gains Ratio-1.170-733%-0.140-0.1400%-0.460+228%-2.115+1407%-1.706+1116%
Quick Ratio--0.4220.4220%2.588-84%1.633-74%1.844-77%
Return On Assets---5.577-5.5770%-2.472-56%-3.974-29%-3.684-34%
Return On Equity----0%-3.7980%-1.3860%-0.8670%
Total Gains Per Share---4.736-4.7360%-1.401-70%-2.228-53%-0.182-96%
Usd Book Value---2311000.000-2311000.0000%5193000.000-145%1081600.000-314%1956125.000-218%
Usd Book Value Change Per Share---4.736-4.7360%-1.401-70%-2.228-53%-0.182-96%
Usd Book Value Per Share---1.459-1.4590%3.278-145%0.683-314%1.235-218%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---12.782-12.7820%-12.448-3%-15.536+22%-15.839+24%
Usd Free Cash Flow---17301000.000-17301000.0000%-19173000.000+11%-24306800.000+40%-23626625.000+37%
Usd Free Cash Flow Per Share---10.920-10.9200%-12.102+11%-15.342+40%-14.913+37%
Usd Free Cash Flow To Equity Per Share---3.065-3.0650%-1.387-55%-2.302-25%-0.349-89%
Usd Market Cap8777022.000+88%1053242.6401053242.6400%1021081.350+3%2937070.398-64%2557476.079-59%
Usd Price Per Share5.540+88%0.6650.6650%0.645+3%1.854-64%1.614-59%
Usd Profit---20251000.000-20251000.0000%-19722000.000-3%-24905800.000+23%-23339000.000+15%
Usd Revenue--570000.000570000.0000%100000.000+470%428600.000+33%409125.000+39%
Usd Total Gains Per Share---4.736-4.7360%-1.401-70%-2.228-53%-0.182-96%
 EOD+6 -2MRQTTM+0 -0YOY+15 -175Y+13 -1910Y+13 -19

4.2. Fundamental Score

Let's check the fundamental score of Vaccinex Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.433
Price to Book Ratio (EOD)Between0-1-3.798
Net Profit Margin (MRQ)Greater than0-35.528
Operating Margin (MRQ)Greater than0-40.149
Quick Ratio (MRQ)Greater than10.422
Current Ratio (MRQ)Greater than10.566
Debt to Asset Ratio (MRQ)Less than11.636
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-5.577
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Vaccinex Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.935
Ma 20Greater thanMa 505.667
Ma 50Greater thanMa 1006.538
Ma 100Greater thanMa 2007.732
OpenGreater thanClose5.256
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,631
Total Liabilities5,942
Total Stockholder Equity-2,311
 As reported
Total Liabilities 5,942
Total Stockholder Equity+ -2,311
Total Assets = 3,631

Assets

Total Assets3,631
Total Current Assets3,349
Long-term Assets282
Total Current Assets
Cash And Cash Equivalents 1,535
Net Receivables 961
Other Current Assets 853
Total Current Assets  (as reported)3,349
Total Current Assets  (calculated)3,349
+/-0
Long-term Assets
Property Plant Equipment 282
Long-term Assets Other 0
Long-term Assets  (as reported)282
Long-term Assets  (calculated)282
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,916
Long-term Liabilities26
Total Stockholder Equity-2,311
Total Current Liabilities
Short-term Debt 221
Short Long Term Debt 75
Accounts payable 2,039
Other Current Liabilities 3,593
Total Current Liabilities  (as reported)5,916
Total Current Liabilities  (calculated)5,928
+/- 12
Long-term Liabilities
Long-term Liabilities  (as reported)26
Long-term Liabilities  (calculated)0
+/- 26
Total Stockholder Equity
Retained Earnings -339,927
Other Stockholders Equity 337,627
Total Stockholder Equity (as reported)-2,311
Total Stockholder Equity (calculated)-2,300
+/- 11
Other
Cash and Short Term Investments 1,535
Common Stock Shares Outstanding 464
Current Deferred Revenue63
Liabilities and Stockholders Equity 3,631
Net Debt -1,288
Net Invested Capital -2,210
Net Working Capital -2,567
Property Plant and Equipment Gross 7,374
Short Long Term Debt Total 247



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
2,842
5,575
22,028
4,604
11,702
9,843
7,977
3,631
3,6317,9779,84311,7024,60422,0285,5752,842
   > Total Current Assets 
2,112
4,974
21,424
4,010
11,286
9,405
7,478
3,349
3,3497,4789,40511,2864,01021,4244,9742,112
       Cash And Cash Equivalents 
1,661
4,180
5,618
2,776
10,596
8,589
6,391
1,535
1,5356,3918,58910,5962,7765,6184,1801,661
       Short-term Investments 
0
0
14,106
0
0
0
0
0
0000014,10600
       Net Receivables 
104
117
639
898
157
0
175
961
9611750157898639117104
       Other Current Assets 
347
677
1,061
336
533
816
912
853
8539128165333361,061677347
   > Long-term Assets 
730
601
604
594
416
438
499
282
282499438416594604601730
       Property Plant Equipment 
730
601
604
594
416
438
499
282
282499438416594604601730
       Other Assets 
0
0
0
0
0
0
0
0
00000000
> Total Liabilities 
6,171
7,347
6,686
6,878
14,314
2,431
2,784
5,942
5,9422,7842,43114,3146,8786,6867,3476,171
   > Total Current Liabilities 
4,440
4,165
6,686
6,878
13,180
2,256
2,537
5,916
5,9162,5372,25613,1806,8786,6864,1654,440
       Short-term Debt 
1,037
2,813
0
0
8,074
215
238
221
2212382158,074002,8131,037
       Short Long Term Debt 
1,037
2,813
0
0
8,074
74
74
75
7574748,074002,8131,037
       Accounts payable 
2,456
1,910
2,322
3,208
3,169
1,061
1,518
2,039
2,0391,5181,0613,1693,2082,3221,9102,456
       Other Current Liabilities 
1,984
1,957
4,364
3,670
1,937
980
781
3,593
3,5937819801,9373,6704,3641,9571,984
   > Long-term Liabilities 
1,731
3,182
0
3,670
1,134
175
247
26
262471751,1343,67003,1821,731
       Long term Debt Total 
1,037
2,813
0
0
0
0
0
0
0000002,8131,037
       Other Liabilities 
694
369
0
0
0
0
0
0
000000369694
> Total Stockholder Equity
-3,329
-13,735
-8,621
-26,237
-26,575
7,412
5,193
-2,311
-2,3115,1937,412-26,575-26,237-8,621-13,735-3,329
   Common Stock
1
1
1
1
3
3
5
0
05331111
   Retained Earnings -339,927-319,676-299,861-277,481-248,630-216,767-187,249-168,527
   Capital Surplus 
53,789
54,123
208,156
222,403
0
0
0
0
0000222,403208,15654,12353,789
   Treasury Stock0000-11-11-11-11
   Other Stockholders Equity 
59,673
60,213
214,469
222,392
250,903
307,270
324,864
337,627
337,627324,864307,270250,903222,392214,46960,21359,673



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue570
Cost of Revenue-119
Gross Profit451451
 
Operating Income (+$)
Gross Profit451
Operating Expense-23,336
Operating Income-22,885-22,885
 
Operating Expense (+$)
Research Development16,455
Selling General Administrative6,881
Selling And Marketing Expenses0
Operating Expense23,33623,336
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1
Other Finance Cost-0
Net Interest Income-1
 
Pretax Income (+$)
Operating Income-22,885
Net Interest Income-1
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,251-25,519
EBIT - interestExpense = -22,886
-20,251
-20,250
Interest Expense1
Earnings Before Interest and Taxes (EBIT)-22,885-20,250
Earnings Before Interest and Taxes (EBITDA)-22,766
 
After tax Income (+$)
Income Before Tax-20,251
Tax Provision-0
Net Income From Continuing Ops-22,012-20,251
Net Income-20,251
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses23,455
Total Other Income/Expenses Net2,6341
 

Technical Analysis of Vaccinex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vaccinex. The general trend of Vaccinex is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vaccinex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vaccinex Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.676 < 6.8701 < 7.51.

The bearish price targets are: 4.432.

Tweet this
Vaccinex Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vaccinex Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vaccinex Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vaccinex Inc. The current macd is -0.22450458.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vaccinex price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vaccinex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vaccinex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Vaccinex Inc Daily Moving Average Convergence/Divergence (MACD) ChartVaccinex Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vaccinex Inc. The current adx is 13.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vaccinex shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Vaccinex Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vaccinex Inc. The current sar is 6.38416023.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vaccinex Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vaccinex Inc. The current rsi is 42.94. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Vaccinex Inc Daily Relative Strength Index (RSI) ChartVaccinex Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vaccinex Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vaccinex price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Vaccinex Inc Daily Stochastic Oscillator ChartVaccinex Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vaccinex Inc. The current cci is -40.06829786.

Vaccinex Inc Daily Commodity Channel Index (CCI) ChartVaccinex Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vaccinex Inc. The current cmo is -12.17538283.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vaccinex Inc Daily Chande Momentum Oscillator (CMO) ChartVaccinex Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vaccinex Inc. The current willr is -71.12453879.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vaccinex is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vaccinex Inc Daily Williams %R ChartVaccinex Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vaccinex Inc.

Vaccinex Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vaccinex Inc. The current atr is 0.5824224.

Vaccinex Inc Daily Average True Range (ATR) ChartVaccinex Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vaccinex Inc. The current obv is 1,811,086.

Vaccinex Inc Daily On-Balance Volume (OBV) ChartVaccinex Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vaccinex Inc. The current mfi is 50.57.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Vaccinex Inc Daily Money Flow Index (MFI) ChartVaccinex Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vaccinex Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-16STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Vaccinex Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vaccinex Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.935
Ma 20Greater thanMa 505.667
Ma 50Greater thanMa 1006.538
Ma 100Greater thanMa 2007.732
OpenGreater thanClose5.256
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vaccinex with someone you think should read this too:
  • Are you bullish or bearish on Vaccinex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vaccinex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vaccinex Inc

I send you an email if I find something interesting about Vaccinex Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Vaccinex Inc.

Receive notifications about Vaccinex Inc in your mailbox!